ATXN3 and Spinocerebellar ataxia type 3: These transgenic mice were generated using the human ataxin-3 sequence [15] with a polymorphism that is present in 70% of MJD patients [25], [28], which permitted the design of a shRNA that specifically targets mutant ataxin-3 [26].